Inari Medical, Inc. (NASDAQ:NARI) Director Donald B. Milder sold 7,000 shares of the stock in a transaction that occurred on Monday, January 11th. The stock was sold at an average price of $84.59, for a total value of $592,130.00. Following the transaction, the director now owns 239,841 shares in the company, valued at $20,288,150.19. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Shares of NASDAQ:NARI opened at $95.94 on Thursday. Inari Medical, Inc. has a twelve month low of $39.55 and a twelve month high of $98.09. The stock’s 50 day moving average is $75.07 and its 200-day moving average is $67.86.

Inari Medical (NASDAQ:NARI) last issued its earnings results on Thursday, November 12th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.16. The firm had revenue of $38.70 million for the quarter, compared to analyst estimates of $26.53 million. The firm’s revenue for the quarter was up 172.5% compared to the same quarter last year. Equities analysts predict that Inari Medical, Inc. will post 0.16 EPS for the current fiscal year.

A number of research firms have issued reports on NARI. Zacks Investment Research upgraded Inari Medical from a “sell” rating to a “hold” rating in a report on Wednesday, November 18th. BTIG Research began coverage on Inari Medical in a report on Wednesday, November 18th. They set a “buy” rating and a $92.00 price target on the stock. Wells Fargo & Company upgraded Inari Medical from an “equal weight” rating to an “overweight” rating and set a $79.00 price target on the stock in a report on Tuesday, December 15th. ValuEngine cut Inari Medical from a “buy” rating to a “hold” rating in a report on Monday, November 2nd. Finally, BidaskClub upgraded Inari Medical from a “buy” rating to a “strong-buy” rating in a report on Friday, January 1st. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Inari Medical currently has a consensus rating of “Buy” and an average target price of $79.14.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Hamilton Lane Advisors LLC purchased a new stake in Inari Medical in the 4th quarter valued at $931,000. First Hawaiian Bank purchased a new stake in Inari Medical in the 4th quarter valued at $454,000. Strs Ohio purchased a new stake in Inari Medical in the 3rd quarter valued at $131,000. Sei Investments Co. purchased a new stake in Inari Medical in the 3rd quarter valued at $476,000. Finally, California State Teachers Retirement System purchased a new stake in Inari Medical in the 3rd quarter valued at $803,000. 17.16% of the stock is owned by institutional investors and hedge funds.

Inari Medical Company Profile

Inari Medical, Inc, a commercial-stage medical device company, focuses on developing products to treat and transform the lives of patients suffering from venous diseases in the United States. It produces ClotTriever for treatment of deep vein thrombosis; and FlowTriever, a thrombectomy system for treatment of pulmonary embolism.

See Also: How do taxes affect a CDs total return?

Insider Buying and Selling by Quarter for Inari Medical (NASDAQ:NARI)

Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.